# Localized High-Risk Soft Tissue Sarcomas Of The Extremities And Trunk Wall In Adults: An Integrating Approach Comprising Standard Vs Histotype-Tailored Neoadjuvant Chemotherapy

> **NCT01710176** · PHASE3 · COMPLETED · sponsor: **Italian Sarcoma Group** · enrollment: 550 (actual)

## Conditions studied

- Localized High-risk Soft Tissue Sarcomas of the Extremities and Trunk Wall in Adults

## Interventions

- **DRUG:** epirubicin 60 mg/m2/day (days 1, 2) and ifosfamide 3 g/m2/day (days 1, 2, 3)
- **DRUG:** gemcitabine 900 mg/m2 (days 1 and 8) and docetaxel 75 mg/m2 (day 8)
- **DRUG:** trabectedin 1.3 mg/m2
- **DRUG:** high-dose ifosfamide 14 g/m2, given in in 14 days
- **DRUG:** etoposide 150 mg/m2/day (days 1, 2, 3) and ifosfamide 3g/m2/day (days 1, 2, 3)
- **DRUG:** gemcitabine 1800 mg/m2 (day 1) and dacarbazine 500 mg/m2 (day 1)

## Key facts

- **NCT ID:** NCT01710176
- **Lead sponsor:** Italian Sarcoma Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-06-01
- **Primary completion:** 2024-06-30
- **Final completion:** 2024-06-30
- **Target enrollment:** 550 (ACTUAL)
- **Last updated:** 2025-11-18

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01710176

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01710176, "Localized High-Risk Soft Tissue Sarcomas Of The Extremities And Trunk Wall In Adults: An Integrating Approach Comprising Standard Vs Histotype-Tailored Neoadjuvant Chemotherapy". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01710176. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*